541 related articles for article (PubMed ID: 30061675)
1. Organoid cultures recapitulate esophageal adenocarcinoma heterogeneity providing a model for clonality studies and precision therapeutics.
Li X; Francies HE; Secrier M; Perner J; Miremadi A; Galeano-Dalmau N; Barendt WJ; Letchford L; Leyden GM; Goffin EK; Barthorpe A; Lightfoot H; Chen E; Gilbert J; Noorani A; Devonshire G; Bower L; Grantham A; MacRae S; Grehan N; Wedge DC; Fitzgerald RC; Garnett MJ
Nat Commun; 2018 Jul; 9(1):2983. PubMed ID: 30061675
[TBL] [Abstract][Full Text] [Related]
2. Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor.
Derouet MF; Allen J; Wilson GW; Ng C; Radulovich N; Kalimuthu S; Tsao MS; Darling GE; Yeung JC
Sci Rep; 2020 Sep; 10(1):14514. PubMed ID: 32884042
[TBL] [Abstract][Full Text] [Related]
3. Differential clonal evolution in oesophageal cancers in response to neo-adjuvant chemotherapy.
Findlay JM; Castro-Giner F; Makino S; Rayner E; Kartsonaki C; Cross W; Kovac M; Ulahannan D; Palles C; Gillies RS; MacGregor TP; Church D; Maynard ND; Buffa F; Cazier JB; Graham TA; Wang LM; Sharma RA; Middleton M; Tomlinson I
Nat Commun; 2016 Apr; 7():11111. PubMed ID: 27045317
[TBL] [Abstract][Full Text] [Related]
4. A comparative analysis of whole genome sequencing of esophageal adenocarcinoma pre- and post-chemotherapy.
Noorani A; Bornschein J; Lynch AG; Secrier M; Achilleos A; Eldridge M; Bower L; Weaver JMJ; Crawte J; Ong CA; Shannon N; MacRae S; Grehan N; Nutzinger B; O'Donovan M; Hardwick R; Tavaré S; Fitzgerald RC;
Genome Res; 2017 Jun; 27(6):902-912. PubMed ID: 28465312
[TBL] [Abstract][Full Text] [Related]
5. Molecular clonality analysis of esophageal adenocarcinoma by multiregion sequencing of tumor samples.
van Nistelrooij AM; van Marion R; Koppert LB; Biermann K; Spaander MC; Tilanus HW; van Lanschot JJ; Wijnhoven BP; Dinjens WN
BMC Res Notes; 2017 Apr; 10(1):144. PubMed ID: 28376920
[TBL] [Abstract][Full Text] [Related]
6. Identification of Subtypes of Barrett's Esophagus and Esophageal Adenocarcinoma Based on DNA Methylation Profiles and Integration of Transcriptome and Genome Data.
Jammula S; Katz-Summercorn AC; Li X; Linossi C; Smyth E; Killcoyne S; Biasci D; Subash VV; Abbas S; Blasko A; Devonshire G; Grantham A; Wronowski F; O'Donovan M; Grehan N; Eldridge MD; Tavaré S; ; Fitzgerald RC
Gastroenterology; 2020 May; 158(6):1682-1697.e1. PubMed ID: 32032585
[TBL] [Abstract][Full Text] [Related]
7. Tracking the genomic evolution of esophageal adenocarcinoma through neoadjuvant chemotherapy.
Murugaesu N; Wilson GA; Birkbak NJ; Watkins T; McGranahan N; Kumar S; Abbassi-Ghadi N; Salm M; Mitter R; Horswell S; Rowan A; Phillimore B; Biggs J; Begum S; Matthews N; Hochhauser D; Hanna GB; Swanton C
Cancer Discov; 2015 Aug; 5(8):821-831. PubMed ID: 26003801
[TBL] [Abstract][Full Text] [Related]
8. Novel Aberrations Uncovered in Barrett's Esophagus and Esophageal Adenocarcinoma Using Whole Transcriptome Sequencing.
Maag JLV; Fisher OM; Levert-Mignon A; Kaczorowski DC; Thomas ML; Hussey DJ; Watson DI; Wettstein A; Bobryshev YV; Edwards M; Dinger ME; Lord RV
Mol Cancer Res; 2017 Nov; 15(11):1558-1569. PubMed ID: 28751461
[TBL] [Abstract][Full Text] [Related]
9. The landscape of selection in 551 esophageal adenocarcinomas defines genomic biomarkers for the clinic.
Frankell AM; Jammula S; Li X; Contino G; Killcoyne S; Abbas S; Perner J; Bower L; Devonshire G; Ococks E; Grehan N; Mok J; O'Donovan M; MacRae S; Eldridge MD; Tavaré S; ; Fitzgerald RC
Nat Genet; 2019 Mar; 51(3):506-516. PubMed ID: 30718927
[TBL] [Abstract][Full Text] [Related]
10. Genomic profiling of esophageal squamous cell carcinoma (ESCC)-Basis for precision medicine.
Yang JW; Choi YL
Pathol Res Pract; 2017 Jul; 213(7):836-841. PubMed ID: 28554745
[TBL] [Abstract][Full Text] [Related]
11. Organoid cultures of early-onset colorectal cancers reveal distinct and rare genetic profiles.
Yan HHN; Siu HC; Ho SL; Yue SSK; Gao Y; Tsui WY; Chan D; Chan AS; Wong JWH; Man AHY; Lee BCH; Chan ASY; Chan AKW; Hui HS; Cheung AKL; Law WL; Lo OSH; Yuen ST; Clevers H; Leung SY
Gut; 2020 Dec; 69(12):2165-2179. PubMed ID: 32217638
[TBL] [Abstract][Full Text] [Related]
12. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
[TBL] [Abstract][Full Text] [Related]
13. The Axl receptor tyrosine kinase is an adverse prognostic factor and a therapeutic target in esophageal adenocarcinoma.
Hector A; Montgomery EA; Karikari C; Canto M; Dunbar KB; Wang JS; Feldmann G; Hong SM; Haffner MC; Meeker AK; Holland SJ; Yu J; Heckrodt TJ; Zhang J; Ding P; Goff D; Singh R; Roa JC; Marimuthu A; Riggins GJ; Eshleman JR; Nelkin BD; Pandey A; Maitra A
Cancer Biol Ther; 2010 Nov; 10(10):1009-18. PubMed ID: 20818175
[TBL] [Abstract][Full Text] [Related]
14. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
Saeed K; Ojamies P; Pellinen T; Eldfors S; Turkki R; Lundin J; Järvinen P; Nisen H; Taari K; Af Hällström TM; Rannikko A; Mirtti T; Kallioniemi O; Östling P
Int J Cancer; 2019 Mar; 144(6):1356-1366. PubMed ID: 30125350
[TBL] [Abstract][Full Text] [Related]
15. Stromal-derived interleukin 6 drives epithelial-to-mesenchymal transition and therapy resistance in esophageal adenocarcinoma.
Ebbing EA; van der Zalm AP; Steins A; Creemers A; Hermsen S; Rentenaar R; Klein M; Waasdorp C; Hooijer GKJ; Meijer SL; Krishnadath KK; Punt CJA; van Berge Henegouwen MI; Gisbertz SS; van Delden OM; Hulshof MCCM; Medema JP; van Laarhoven HWM; Bijlsma MF
Proc Natl Acad Sci U S A; 2019 Feb; 116(6):2237-2242. PubMed ID: 30670657
[TBL] [Abstract][Full Text] [Related]
16. Tumor Evolution and Drug Response in Patient-Derived Organoid Models of Bladder Cancer.
Lee SH; Hu W; Matulay JT; Silva MV; Owczarek TB; Kim K; Chua CW; Barlow LJ; Kandoth C; Williams AB; Bergren SK; Pietzak EJ; Anderson CB; Benson MC; Coleman JA; Taylor BS; Abate-Shen C; McKiernan JM; Al-Ahmadie H; Solit DB; Shen MM
Cell; 2018 Apr; 173(2):515-528.e17. PubMed ID: 29625057
[TBL] [Abstract][Full Text] [Related]
17. Genomic evidence supports a clonal diaspora model for metastases of esophageal adenocarcinoma.
Noorani A; Li X; Goddard M; Crawte J; Alexandrov LB; Secrier M; Eldridge MD; Bower L; Weaver J; Lao-Sirieix P; Martincorena I; Debiram-Beecham I; Grehan N; MacRae S; Malhotra S; Miremadi A; Thomas T; Galbraith S; Petersen L; Preston SD; Gilligan D; Hindmarsh A; Hardwick RH; Stratton MR; Wedge DC; Fitzgerald RC
Nat Genet; 2020 Jan; 52(1):74-83. PubMed ID: 31907488
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive Genomic Profiling of Advanced Esophageal Squamous Cell Carcinomas and Esophageal Adenocarcinomas Reveals Similarities and Differences.
Wang K; Johnson A; Ali SM; Klempner SJ; Bekaii-Saab T; Vacirca JL; Khaira D; Yelensky R; Chmielecki J; Elvin JA; Lipson D; Miller VA; Stephens PJ; Ross JS
Oncologist; 2015 Oct; 20(10):1132-9. PubMed ID: 26336083
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological targeting of p38 MAP-Kinase 6 (MAP2K6) inhibits the growth of esophageal adenocarcinoma.
Lin S; Liu K; Zhang Y; Jiang M; Lu R; Folts CJ; Gao X; Noble MD; Zhao T; Zhou Z; Lan X; Que J
Cell Signal; 2018 Nov; 51():222-232. PubMed ID: 30102978
[TBL] [Abstract][Full Text] [Related]
20. Targeted Sequencing of Sorted Esophageal Adenocarcinoma Cells Unveils Known and Novel Mutations in the Separated Subpopulations.
Isidori F; Bozzarelli I; Mastracci L; Malvi D; Lugaresi M; Molinari C; Söderström H; Räsänen J; D'Errico A; Fiocca R; Seri M; Krishnadath KK; Bonora E; Mattioli S
Clin Transl Gastroenterol; 2020 Sep; 11(9):e00202. PubMed ID: 33094962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
